1	Title: Real-world evidence: telemedicine for complicated cases of urinary tract infection
2	
3	Running Title: RWE for telemedicine and complicated UTI
4	
5	Authors:
6	Natalie M. Daumeyer ¹ , Daniel Kreitzberg ¹ , Kathleen M. Gavin ^{1,2} , Timothy A. Bauer ^{1,2,*}
7	
8	¹ Everly Health, Inc., Austin, TX, USA
9	² University of Colorado Anschutz Medical Campus, Aurora, CO, USA
10	
11	*Corresponding author
12	Email: <u>tbauer@everlyhealth.com</u>
13	
14	References: 40
15	Tables: 4
16	Figures: 2
17	Appendices: 1
18 19	Article text: 3,366 words, not including title page, abstract, references, tables, figures, or appendices
20	Abstract: 265 words
21 22	Key words: antibiotic compliance; cystitis; telehealth; telemedicine; urinary tract infections
23	Abbreviations:
24	STIs, sexually transmitted infections; UTIs, urinary tract infections
 25	5116, servani y dansmitted micedons, e 115, annal y daet micedons
26	
27	Abstract
28	Background: Telemedicine programs for the treatment of urinary tract infections (UTIs) offer a
29	opportunity to reduce burdens on patients and providers. However, these programs are typically

an

restricted to patients with uncomplicated UTIs. This real-world analysis evaluated treatment and
 resolution rates in a large-scale, national UTI telemedicine program inclusive of patients with
 uncomplicated and complicated UTIs.

33 **Methods and findings**: We conducted a retrospective analysis of data obtained from a 34 commercially available telemedicine program for the treatment of UTIs among adult women in the US between 2017 and 2021 (n=51,474). The primary outcomes were the number of women 35 36 who presented with symptoms of uncomplicated UTI, complicated UTI, and vaginal infection; prescription use and antibiotic type; symptom resolution within 7 days after appointment; and 37 38 treatment failure or relapse. Most patients reported frequent urination (94.4%), urgency (94.5%), 39 and dysuria (97.6%). Those with uncomplicated UTI symptoms represented the majority of 40 patients (61.6%); however, a substantial number of patients (36.5%) also reported at least 1 41 symptom associated with a complicated UTI. One-fifth of patients (19.2%) reported at least 1 co-42 occurring symptom of vaginal infection or sexually transmitted infection. Across all treated 43 patients, 94.0% received recommended antibiotics according to the clinical protocol. Of the 44 treated patients who provided follow-up data (n=3,521), 89.7% reported 7-day symptom resolution. Symptom resolution rates were similar between patients with uncomplicated UTI 45 46 symptoms (90.8%) and complicated UTI symptoms (87.9%), and symptom resolution among all 47 treated patients (89.7%) was similar to reports for in-person standard of care. **Conclusions:** These findings suggest that large-scale telemedicine programs for the treatment of 48 49 UTIs can be effective in the treatment of complicated UTIs.

51 Introduction

52 Urinary tract infections (UTIs) are some of the most common infections, accounting for millions of visits to healthcare facilities every year [1]. The use of urinalysis in emergency departments to 53 54 diagnose suspected UTIs has increased from 23% in 2007 to 27% in 2016 [2]. During these visits, patients can spend more than 2 hours waiting for and receiving care, creating a burden for 55 patients [3]. Using telemedicine as an alternative model of care for patients with UTIs would 56 57 reduce the amount of time patients spend seeking treatment, while freeing up important resources in often over-burdened urgent care and emergency departments, as well as primary care clinics 58 59 [4,5]. UTIs make up 0.7% of outpatient services, according to projections from US registries [1]. 60 Between 1996 and 2001, an average of 7 million women visited healthcare centers in the US for 61 uncomplicated UTIs [6]. There were 10.5 million ambulatory visits for UTIs in the US in 2007 62 (accounting for approximately 1% of all ambulatory visits), of which, 21.3% were to emergency departments [7]. Consultations for UTIs represent between 1% and 6% of all medical visits 63 64 $(\sim 7 \square$ million visits and $\sim 1.6 \square$ billion \square annually) [8]. Previous research has shown that 65 telemedicine treatment programs are effective for women presenting with uncomplicated UTI 66 symptoms [9-15]. These programs, which largely rely on the application of inclusion/exclusion criteria according to self-reported symptoms and empirical use of antibiotics [16], are similar to 67 in-person care and reduce time to recovery compared with diagnosis using urinalysis [16,17]. 68 However, a limitation of these programs is the exclusion of patients who self-reported symptoms 69 70 of complicated UTIs (e.g., fever, nausea) or vaginal infections (e.g., vaginal discharge, vaginal 71 irritation) [9,11-14]. Thus, it is unclear how effective or safe telemedicine programs can be for 72 patients with these clinical profiles.

Women with symptoms of complicated UTIs (e.g., pyelonephritis) are usually referred to in-person care to receive intravenous antibiotics and/or undergo urinalysis to determine the appropriate antibiotic regimen [18,19]. However, some complicated UTI cases can be managed at home without admittance to an emergency department. Researchers have thus begun to question whether higher-risk patients, such as those who report symptoms of pyelonephritis or more complicated UTI, can be treated via telemedicine [15,18,20].


79 In a similar manner, women with vaginal symptoms are often referred to in-person care to rule out other diagnoses, such as sexually transmitted infections (STIs) and vaginal infections 80 81 [16,21,22]. However, even cases of suspected STI may be managed by remote sample collection 82 and telemedicine services [23]. Recent evidence has shown that vaginal discharge does not reduce the likelihood of a UTI [24], contradicting earlier studies advocating for in-person 83 84 treatment for women with vaginal symptoms [16]. Thus, with proper symptom screening, which 85 can be implemented virtually, a process for ruling in or out vaginal infections and STIs may be 86 accomplished [25]. Patients with symptoms of complicated UTI or vaginal infection may benefit 87 from a telemedicine approach to care, but current studies evaluating the value of telemedicine 88 have excluded these patients. It remains unknown whether telemedicine provides an alternative, 89 effective pathway to care without compromising on quality.

90 This study examined real-world data from a large telemedicine program that sought to 91 provide treatment for women with UTI symptoms. This UTI telemedicine program is different 92 from previously evaluated programs [15] in the following ways: 1) symptoms reported during 93 the initial screening are included, 2) patients who reported symptoms of complicated UTI and 94 vaginal infection were included, and 3) physicians were given discretion as to whether and how 95 to treat women who reported symptoms of complicated UTI or vaginal infection. The primary

96	outcome measures were the number of women who presented with symptoms of uncomplicated
97	UTI, complicated UTI, and vaginal infection; prescription use and antibiotic type; symptom
98	resolution within 7 days after appointment; and treatment failure or relapse.
99	
100	Methods
101	Ethics
102	This study is a retrospective analysis of real-world data from a nationwide commercial
103	telemedicine program for the treatment of UTIs. The project was deemed exempt from IRB
104	review by WCG Institutional Review Board (IRB00000533) because it does not meet the
105	definition of human subjects research as defined in federal regulation 45 CFR 46.102.
106	
107	Study population and data collection
108	Individuals in the US seeking care for UTI symptoms between November 2017 and November
109	2021 completed a digital screening process to determine their eligibility for telemedicine
110	services. Patients were excluded for the following reasons: younger than 18 years of age, male,
111	pregnant or breastfeeding, immunocompromising conditions (e.g., HIV, lupus), history of kidney
112	condition, history of urinary condition, history of urologic procedure, history of resistant
113	organisms, or inpatient stay at a healthcare facility within the past 3 months. For this protocol,
114	prior to the COVID-19 pandemic, women aged 65 years or older were excluded if they were
115	currently taking more than 5 prescription medications; this contraindication was removed during
116	the pandemic because of restricted access to in-person care. Cancelled/missed appointments,
117	duplicate records, and follow-up appointments occurring within 30 days after the initial
118	appointment were excluded from the analysis set. Those meeting the criteria reported their

- symptoms through the digital screener and scheduled a telemedicine consultation. Patients who
- 120 reported symptoms of a complicated UTI or vaginal infection were able to schedule a
- telemedicine consultation. Immediately following their consultation, patients received a
- 122 satisfaction questionnaire. After 7 days, patients received a follow-up questionnaire to assess
- 123 their symptom resolution. All patients who reported unresolved symptoms received follow-up
- telemedicine services. Fig 1 shows the participant selection process for this cohort study.

125



- 126
- 127

Fig 1. Study flow chart

- 129 *Physician information and the clinical protocol*
- 130 The median number of consultations was 79 (IQR=623) among 84 physicians. Physician
- 131 specialties varied and included 51.2% (n=43) family medicine, 29.8% (n=25) internal medicine,
- 132 11.9% (n=10) emergency medicine, and 4.8% (n=4) preventative medicine, as well as 1
- 133 physician who was trained in both internal and emergency medicine and 1 physician who was
- trained as a radiologist. A clinical protocol provided guidance for physicians to diagnose and
- treat uncomplicated UTIs using the telemedicine platform. The protocol outlined

136	contraindications, considerations for treatment, and recommended antibiotic regimens (see S1
137	Appendix) [18,22,26]. All physicians were trained on the protocol, which was available for
138	reference during consultations. The protocol recommended that patients with symptoms of
139	complicated UTIs or vaginal infection be referred to in-person care. However, physicians were
140	permitted to use their discretion to treat via telemedicine or refer to in-person care. STIs were
141	ruled out during physician consultation based on answers provided on the questionnaire. If
142	providers were unsure about treating a patient, they could escalate the issue to the telemedicine
143	program directors for additional guidance.
144	
145	Measures
146	Demographic characteristics. Patients were asked their age (in years) and sex during the
147	digital screening process before the UTI consultation. The first 3 digits of each patient's zip code
148	were used to determine geographic location.
149	Symptom presentation groups. Patients reported the presence of the following 4
150	uncomplicated UTI symptoms: urinary frequency, urinary urgency, dysuria (pain or burning
151	while urinating), and hematuria (blood in the urine). Patients reported the presence of the
152	following complicated UTI symptoms: an oral temperature greater than 99.5 °F; new onset of
153	nausea and/or vomiting; new onset of feelings of general achiness/feeling unwell; back,
154	abdominal, side, or groin pain; international travel within the past 6 months; and dehydration
155	within the past 2 to 3 weeks [5,27,28]. Patients identified the presence of any vaginal infection
156	symptoms: green, yellow, clear, or white discharge; odor from urine/discharge; and vaginal
157	itching, blisters, lesions, or rash. Patients were grouped into 3 categories according to their
158	reported symptom presentation: uncomplicated UTI symptoms, complicated UTI symptoms, and

- 159 other (see Table 1). Appointments for recurrent infection (i.e., at least 2 appointments in 6
- 160 months, aside from relapse, or at least 3 appointments in 12 months, aside from relapse) were
- 161 considered a complicated UTI, as long as the patient reported UTI symptoms (even if the patient
- 162 had reported only symptoms of uncomplicated UTI during their recurrent visits) [19]. The
- 163 presence or absence of vaginal symptoms was also assessed.
- 164

Symptom Description Group		N (%) (N=51,474)	
Uncomplicated UTI ^{1,3}	 Patients reporting ≥2 of the 4 UTI symptoms, with or without symptoms of vaginal infection Not a recurrent infection (first infection in 6 months, or <3 infections in 12 months) 	31,730 (61.6)	
Complicated UTI ^{2,3}	 Patients who reported ≥1 of the 4 UTI symptoms AND ≥1 symptom of complicated infection, with or without symptoms of vaginal infection (regardless of recurrent infection) OR 	18,788 (36.5)	
	OK		
	• Any patient with recurrent infection (≥2 infections in 6 months or ≥3 infections in 12 months) with or without symptoms of vaginal infection (regardless of having only uncomplicated UTI symptoms)		
Other ³	 Patients reporting ≤1 of the 4 UTI symptoms, without symptoms of complicated infection, with or without symptoms of vaginal infection Patients reporting none of the 4 UTI symptoms with ≤1 of the complicated infection symptoms, with or without symptoms of vaginal infection Regardless of recurrent infection 	956 (1.9)	

165 **Table 1. Symptom groups and descriptions.**

166 UTI, urinary tract infection.

¹Uncomplicated UTI symptoms consisted of urinary frequency, urinary urgency, dysuria, and

168 hematuria.

- ²Complicated UTI symptoms consisted of an oral temperature greater than 99.5 °F; new onset of
- 170 nausea and/or vomiting; new onset of feelings of general achiness/not feeling well; back,
- abdominal, side, or groin pain; international travel within the past 6 months; and dehydration

172 within the past 2–3 weeks.

- ³Symptoms of vaginal infections consisted of green, yellow, clear, or white discharge; odor from
- 174 urine or discharge; and vaginal itching, blisters, lesions, or rash.

175

176	Prescription use and antibiotic type. Prescription use and antibiotic type were measured
177	by analyzing the number of appointments that resulted in prescriptions and the type and number
178	of medications that were prescribed. A standard clinical protocol was developed based on
179	guidelines for uncomplicated UTIs; thus, the recommended antibiotics were nitrofurantoin,
180	trimethoprim-sulfamethoxazole, and fosfomycin (see S1 Appendix) [18,22,26]. No standardized
181	protocol was developed for complicated UTIs and/or symptoms of vaginal infection. Physicians
182	were permitted to manage these cases according to their evaluation and discretion. However,
183	specific population-guided protocols were developed (e.g., for women older than 65 years,
184	patients with dual infections).
185	Symptom resolution. Patients received a survey 7 days after their appointment asking
186	them to indicate whether their symptoms had resolved.
187	Treatment failure and relapse. Appointments that occurred within 30 days after an initial
188	appointment were considered follow-up visits and reported as treatment failure or relapse. These
189	visits were excluded from the original analyses and were instead reported as outcomes of the
190	initial appointment. Due to insufficient data (e.g., it is unclear if most patients experienced any
191	symptom resolution between appointments), treatment failure and relapse were reported together
192	because these groups were indistinguishable.
193	
194	Statistical methods

195 Descriptive statistics were used to summarize the study sample, including frequencies, means,

196 SDs, medians, and IQRs. Specifically, data were presented to examine prescription use and

197 symptom resolution by age and US census region, as well as by grouping those with

198	uncomplicated UTIs, complicated UTIs, and symptoms of vaginal infection. Number of
199	prescriptions received, type of prescription, symptom resolution, and number of treatment
200	failures/relapses by symptom profile category were also assessed. Symptom resolution rates were
201	compared, using chi-square tests, between the complicated and uncomplicated UTI symptom
202	groups and between all women who received a prescription medication with symptom resolution
203	among 8 comparator studies, for a total of 9 tests [14,29-35]. Bonferroni correction was used to
204	account for multiple tests, and p-values < 0.005 were considered significant. All descriptive
205	statistics and chi-square tests were calculated in R (version 4.0.5) for Macintosh.
206	
207	Results
208	The analysis set (n=51,474) included data from appointments with patients between the ages of
209	18 and 84 years (mean=39.4, SD=14.7). Most patients were between the ages of 22 to 46 years
210	(n=30,423, 59.1%), and the South census geographic region had the greatest number of patients

211 (n=20,172, 39.2%; see Table 2).

212

213 Table 2. Patient characteristics.¹

	N (%)
Characteristics	(N=51,474)
Age (years)	
18–21	3,791 (7.4)
22-45	30,423 (59.1)
46–65	14,449 (28.1)
≥66	2,811 (5.5)
Region (US Census Region) ²	
South	20,172 (39.2)
West	17,851 (34.7)
Midwest	9,970 (19.4)

	Northeast	3,481 (6.8)							
214	¹ Raw data counts by age and geographic region for each app	ointment. Individuals who used the							
215	program multiple times appear more than once in this table.	Alaska Arizona California							
216 217	² Regions were determined via the US Census regions. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington,								
217	Wyoming. Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New								
219	York, Pennsylvania, Rhode Island, Vermont. Midwest: Illinois, Indiana, Iowa, Kansas,								
220	Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin.								
221	South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky,								
222	Louisiana, Maryland, Mississippi, North Carolina, Oklahoma	a, South Carolina, Tennessee, Texas,							
223 224	Virginia, West Virginia.								
225	Symptom presentation								
226	Overall, symptom prevalence was high for urinary frequency	v (n=48,574, 94.4%), urinary							
227	urgency (n=48,662, 94.5%), and dysuria (n=50,244, 97.6%),	while fewer patients reported							
228	hematuria (n=8,381, 16.3%). The majority of appointments ((n=31,730, 61.6%) consisted of							
229	patients with uncomplicated UTI symptoms, but a substantia	l number (n=18,788, 36.5%)							
230	reported complicated UTI symptoms (see Table 1). The remain	aining appointments (n=956, 1.9%)							
231	consisted of patients in the other symptoms group. In total, 9	,894 (19.2%) reported at least 1							
232	symptom of vaginal infection: 5,142 (16.2%) in the uncompl	licated UTI symptoms group, 4,618							
233	(24.6%) in the complicated UTI symptoms group, and 134 (2	14.0%) in the other symptoms group.							
234									
235	Prescription use and antibiotic choice								
236	Patients from 50,826 (98.7%) appointments received at least	1 prescription, with 2,818 (5.5%)							
237	receiving more than 1 prescription. Patients from 44,304 (86	.1%) appointments received 1							

- antibiotic, 2,320 (4.5%) received at least 1 antibiotic and an additional medication (e.g.,
- phenazopyridine or fluconazole), 498 (1.0%) received 2 or more antibiotics without an additional

240	medication, and 5 (<0.01%) received 1 or more other medications without an antibiotic.
241	Prescription data were unavailable for 3,966 (7.7%) patient appointments on the platform.
242	Overall, clinical protocol adherence to recommended prescribing patterns was high
243	(n=43,932, 94.0%), and patients were most likely to receive prescriptions for antibiotics that
244	were recommended in the clinical protocol (see Table 3). This pattern was consistent across
245	patient groups: uncomplicated UTI symptoms (n=27,128, 94.4%), complicated UTI symptoms
246	(n=16,070, 93.7%), and other symptoms group (n=772, 88.0%). Most women who reported at
247	least 1 vaginal symptom, in addition to UTI symptoms, received a recommended antibiotic
248	(n=8,396, 84.9%).

Table 3. Sympton	m groups and	prescription c	ounts.	Ι	1	T	1	T
Symptom Group	Received a Prescription ¹ N (%)	Unknown Prescription ² N (%)	Received Antibiotic N (%) ³	Received "Recommended" Antibiotic N (%) ⁴	Nitrofurantoin N (%) ⁵	TMP-SMX N (%) ⁵	Fosfomycin N (%) ⁵	Ciprofloxacin (Regular or XR) N (%) ^{5,6}
Total N=51,474 (100%)	50,826 (98.7)	3,699 (7.2)	46,754 (92.0)	43,932 (94.0)	24,581 (52.6)	19,404 (41.5)	23 (0.0)	2,431 (5.2)
UTI N=50,518 (98.1%)	49,903 (98.8)	3,657 (7.2)	45,877 (91.9)	43,160 (94.1)	24,200 (52.7)	19,010 (41.4)	23 (0.0)	2,346 (5.1)
Uncomplicated N=31,730 (62.8%)	31,431 (99.1)	2,471 (7.8)	28,727 (91.4)	27,128 (94.4)	15,235 (53.0)	11,913 (41.5)	15 (0.0)	1,402 (4.9)
Complicated N=18,788 (37.2%)	18,472 (98.3)	1,186 (6.3)	17,150 (94.8)	16,070 (93.7)	8,965 (52.3)	7,097 (41.4)	8 (0.0)	944 (5.5)
Other N=965 (1.9%)	923 (95.6)	42 (4.4)	877 (95.0)	772 (88.0)	381 (43.4)	394 (44.9)	0 (0.0)	85 (9.7)

249

250 TMP-SMX, trimethoprim-sulfamethoxazole; UTI, urinary tract infection; XR, extended-release.

¹Patients who received >1 prescription are only included once in this column. 251

²Some patients received a prescription, but there was no information about the prescription available in the dataset. 252

³Percentage represents the number of patients who received ≥ 1 antibiotics out of the total number who received a prescription. Patients 253

who received >1 type of antibiotic are only included once. 254

⁴A recommended antibiotic is defined by the clinical protocol, not by the patient's self-reported symptoms, and include nitrofurantoin, 255

TMP-SMX, and fosfomycin. The percentage represents the number of patients who received a recommended antibiotic out of the total 256

- number who received an antibiotic prescription. Note that 76 people received a prescription for nitrofurantoin and TMP-SMX; they
 are only listed once in this column.
- ⁵The percentages represent the number of patients who received that prescription out of the number of patients who received an
- 260 antibiotic.
- ⁶Ciprofloxacin was an alternative regimen in the clinical protocol.
- 262

Symptom resolution 264

265	Symptom resolution data from the 7-day follow-up survey were available for 3,541 women,
266	including 2,193 women in the uncomplicated UTI group, 1,241 women in the complicated UTI
267	group, and 107 women in the other symptoms group. Across all groups, 99.4% of patients
268	(n=3,521) received a prescription, and the majority of these patients reported 7-day symptom
269	resolution (89.7%, n=3,160) compared with less than half of patients who did not receive a
270	prescription (40.0%, n=8; see Table 4). The symptom resolution rate in the complicated UTI
271	group was lower than that of the uncomplicated UTI group; however, this difference was not
272	significant (see Fig 2). Among those with a UTI and at least one symptom of vaginal infection,
273	the symptom resolution rates were similar for those with uncomplicated UTIs (86.2%) and
274	complicated UTIs (85.5%). Across all groups, the symptom resolution rate among patients who
275	received a prescription within this study was significantly higher than 4 of the 8 comparator
276	studies ($\Box^2 = 20.0-374.1$, p<0.001), significantly lower than 1 study ($\Box^2 = 11.9$, p<0.001), and
277	not significantly different from the remaining 3 studies (see Fig 2).

278

Name	Proportion Resolved (99% CI)					
UTI Telemedicine Platform All (n=3,521)*	89.7% (88.4-91.1)				-	
Uncomplicated UTI (n=2,185)	90.8% (89.2-92.4)				-	
Complicated UTI (n=1,230)	87.9% (85.5-90.3)					
Other (n=106)	89.6% (82.0-97.3)			_	-	_
Uncomplicated UTI & vaginal symptom (n=276)	86.2% (80.9-91.6)					
Complicated UTI & vaginal symptom (n=262)	85.5% (79.9-91.1)					
Spencer et al. (1994) (n=502)	86.1% (82.1-90.0)			_		
Stein (1999) (n=446)	89.7% (86.0-93.4)					
Kavatha et al. (2003) (n=133)	99.2% (97.3-101.2)					-
Arredondo-García et al. (2004) (n=285)	86.3% (81.1-91.6)					
Ferry et al. (2007) (n=643)	60.2% (55.2-65.2) -	-				
Gupta et al. (2007) (n=308)	89.9% (85.5-94.4)					
Blozik et al. (2011) (n=499)	78.2% (73.4-82.9)		-	-		
Bollestad et al. (2015) (n=238)	79.0% (72.2-85.8)	60.0	70.0	80.0	90.0	100.

- Fig 2. Forest plot of symptom resolution rates and 99% confidence intervals among all
- consultations, by UTI symptom group, and 8 previous studies' reported rates. *"UTI 281
- Telemedicine Platform All" refers to all consultations with associated 7-day follow-up symptom 282

- resolution data from the current study, followed by each symptom category. Among the
- comparator studies, symptom resolution was measured on different days, including the
- following: 3 days [35], 4 days [14], 4 to 7 days [31], 5 to 9 days [32,34], 7 days [30], 8 to 10
- days [33], and 9 to 15 days [29]. Of the 8 comparator studies, 7 used in-person standard-of-care
- 287 [14,29-34] and 1 used telemedicine services [35]. If the comparator study was a clinical trial with
- a control group, then symptom resolution rates were only compared with treatment groups who
- received antibiotics [14].
- 290

Table 4. Symptom resolution stratified by symptom group and receiving a prescription or
 not.¹

Symptoms	N (%)												
	Uncomplicate d UTI Symptoms (n=2,193)		Complicated UTI Symptoms (n=1,241)		Other Symptoms (n=107)		Uncomplicated UTI & Vaginal Symptom (n=276)		Complicated UTI & Vaginal Symptom (n=262)		Total		
	Rx	No Rx	Rx	No Rx	Rx	No Rx	Rx	No Rx	Rx	No Rx	Rx	No Rx	Total
Resolved	1,984 (90.8)	4 (50.0)	1081 (87.9)	4 (36.4)	95 (89.6)	0 (0.0)	238 (86.5)	0 (0.0)	223 (86.4)	1 (25.0)	3,160 (89.7)	8 (40.0)	3,168 (89.5)
Unresolved	201 (9.2)	4 (50.0)	149 (12.1)	7 (63.6)	11 (10.4)	1 (100.0)	37 (13.5)	1 (100.0)	35 (13.6)	3 (75.0)	361 (10.3)	12 (60.0)	373 (10.5)
Total	2,185	8	1,230	11	106	1	275	1	258	4	3,521	20	3,541

293 Rx, prescription; UTI, urinary tract infection.

¹"Rx" includes individuals who were prescribed any prescription medication.
 295

296 Treatment failure and relapse

Overall, 1,156 (2.2%) patients returned to use the program within 30 days after their original

consultation: 264 patients (22.8%) returned within 7 days, 328 patients (28.4%) within 8 to 14

days, and 564 patients (48.8%) between 15 and 30 days after the initial appointment.

301 Discussion

302 To the authors' knowledge, this is the largest analysis of real-world data from a telemedicine 303 service for treating UTIs to date. Data from 51,474 visits over 4 years indicated that patients 304 from 98.1% of appointments self-reported at least 2 symptoms of uncomplicated or complicated 305 UTIs, with dysuria being the most commonly reported symptom. More than half (52.4%) of the 306 sample reported at least 1 symptom of complicated UTI or vaginal infection. Most appointments 307 (98.7%) resulted in a prescription, and prescription use and type were similar regardless of 308 patient-reported symptoms (uncomplicated UTI, complicated UTI, or vaginal infection). Most 309 patients (94.0%) with available prescription data received antibiotics that were recommended in 310 the protocol (nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin). 311 Of patients with available follow-up survey data, 89.5% reported symptom resolution, 312 and resolution rates were similar between uncomplicated and complicated UTI groups. 313 Furthermore, the symptom resolution rate across all UTI categories was similar to previous 314 research on UTI telemedicine programs evaluating only uncomplicated UTI patients. Only 2.2% 315 of patients returned to the program within 30 days after an initial appointment, suggesting low 316 treatment failure and relapse rates. Resolution rates among uncomplicated and complicated UTIs 317 were also similar to, or better than, previous reports of in-person standard of care (see Fig 2). 318 Taken together, this analysis demonstrates the effectiveness of large-scale UTI telemedicine 319 programs and extends those observations to include patients who self-report symptoms of 320 complicated UTIs or vaginal infections. Although this study made no direct measurements 321 regarding safety, a retrospective study evaluating the safety and efficacy of telemedicine 322 management of uncomplicated UTIs in 526 women reported that teleprescription of antibiotics is

323 as safe as prescriptions initiated during in-person consultations [35]. Overall, 78% of patients

reported complete symptom resolution 3 days following teleconsultation, while 14% reported a
decrease in uncomplicated UTI symptoms. Four percent reported deterioration, such as increased
pain, flank pain, or fever, and 5% reported antibiotic adverse effects [35].

327 Previous research has reported that women perform well at self-diagnosing UTIs [36]. 328 Despite self-reporting symptoms of complicated UTIs or vaginal infections, these data support 329 the notion that the women using this telemedicine program were accurately able to self-identify 330 that they had a UTI. Furthermore, through discussions with physicians, these patients may have 331 clarified the presence and severity of complicated UTIs or vaginal symptoms, which may have 332 emboldened physicians to provide care for women who self-reported these symptoms at intake. 333 Women who self-reported complicated UTI and vaginal symptoms had similar resolution rates 334 compared with those who reported uncomplicated UTIs symptoms. Thus, these data suggest that 335 a telemedicine approach to identification and treatment of more complicated UTIs and vaginal 336 symptoms may be effective. Further work to determine appropriate sub-grouping and 337 standardized protocols for these conditions is likely warranted. Of note, if the program had 338 excluded patients who reported complicated UTI or symptoms of vaginal infection, 24,064 339 women (approximately half of the sample) would have required in-person care, either through 340 primary care, urgent care, or emergency department visits.

At scale, telemedicine programs that include uncomplicated and complicated UTIs could be a complementary offering at primary care clinics. This complementary service may result in reduced provider burdens within those settings, as well as within urgent care or emergency departments, freeing up valuable resources, without compromising quality of care or resolution rates. Undeniably, telemedicine access for UTI assessment and treatment can lessen the patient burden of in-person care. Future studies may identify the most effective protocols for integrating

such services into the existing primary care setting, or even into urgent care centers andemergency departments.

349 Another noteworthy outcome of this analysis was that telemedicine physician adherence 350 to recommended antibiotic protocols was higher than previously reported, according to 351 concordance with the Infectious Diseases Society of America guidelines for antibiotics to treat 352 UTIs [37,38]. The telemedicine physicians in this sample were adherent to these guidelines for 353 94.0% of appointments that resulted in antibiotic prescriptions. This high adherence rate may 354 have been due to the implementation of the protocol and ease of use [39]. Moreover, provider 355 prescribing practices were regularly audited to assure compliance. The recommended antibiotics 356 in the clinical protocol were based on the guidelines for patients with uncomplicated UTIs 357 [26,40]. Although not detailed in the current clinical protocol, the recommended antibiotic regimens may differ for patients exhibiting symptoms of pyelonephritis or complicated infection 358 359 [40]. Telemedicine programs that allow for patients with symptoms of complicated UTIs or 360 vaginal infections to receive appointments should include specific instructions for assessing the 361 severity of the infection, the potential need for STI testing, and other medications that should be 362 considered if a UTI diagnosis is not suspected.

363

364 *Limitations*

As with all real-world evidence, the data used in this analysis were limited by what was collected through the clinical program. The present analysis relied on inferred diagnosis determined from digital responses and patient-reported symptoms at intake. Diagnoses made during treatment consultations were not obtained. As telemedicine programs become more ubiquitous, incorporating post-encounter diagnosis codes would provide greater granularity and

370 understanding of treatment patterns and outcomes, particularly for those with more complicated 371 cases or other symptoms that may be addressed as part of the telemedicine encounter. Integrating 372 these types of programs into electronic health records diagnosis information would allow 373 researchers to identify patients who inaccurately report their symptoms. Future work is needed to 374 determine discrepancies between patient-reported symptoms on intake and physicians' diagnoses 375 based on direct patient encounters. This knowledge would help to expand clinical protocols to 376 include guidance for determining the risk levels and appropriate next steps for patients who 377 report symptoms of complicated UTI or vaginal infection.

378 The current analysis evaluated symptom resolution data for a total of 3,541 appointments, 379 representing only 6.9% of the population. Although this still represents a large cohort in both the 380 uncomplicated and complicated UTI groups, we can only speculate a similar rate of symptom 381 resolution over the entire sample population. Notably, patients who did not experience symptom 382 resolution were offered additional care, including referral to in-person care, and as such no 383 symptom resolution data may have been available. A small percentage of patients (2.2%)384 returned to use the program within 30 days after the initial consultation, suggesting that most 385 patients experienced a full recovery or sought in-person/other care, a feature this analysis cannot 386 resolve. Patient follow-up data are needed to better understand symptom resolution when using 387 direct-to-consumer telemedicine services. Future research may provide insight into how to 388 ensure patients self-report symptom resolution, or perhaps, how data from electronic health 389 records may be used to assess follow-up engagement with in-person care services.

390

391 Conclusion

392	Telemedicine services make it easier and faster for patients to receive treatment for UTIs by
393	eliminating travel and waiting time at emergency rooms. This analysis demonstrates that
394	telemedicine programs are an effective and scalable option for treatment of UTIs, even for
395	women who self-report symptoms of complicated UTIs or vaginal infection. Most patients in the
396	program exhibited symptoms of uncomplicated or complicated UTIs. Of those patients with
397	available follow-up data, most experienced symptom resolution within 7 days after their
398	appointment. Implementing and scaling UTI telemedicine programs and including women who
399	self-report symptoms of complicated UTI or vaginal infection can reduce the burden on urgent
400	care facilities and emergency departments, without compromising on the quality of care.

402

403 Acknowledgments

- 404 The authors would like to acknowledge the following people who developed and managed the
- 405 telemedicine program evaluated in this study: Yvette Gaudreau, Lara Goorland, Anthony
- 406 Dearman, Gabe Gaviola, Adina Schwartz, Jennifer Jing, Emily Miller, and Doug Elwood.
- 407 Additionally, writing support was provided by Virgo Health.

408

409

410 **Competing Interests**

- 411 Natalie Daumeyer, Daniel Kreitzberg, Kathleen Gavin, and Timothy Bauer were all employees
- 412 of Everly Health, Inc. at the time this analysis was conducted.

414	References
415	1. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007.
416	Vital Health Stat 13. 2011;(169):1-38.
417	2. Chou SC, Baker O, Schuur JD. Changes in emergency department care intensity from
418	2007-16: analysis of the National Hospital Ambulatory Medical Care survey. West J Emerg
419	Med. 2020;21(2):209-216. doi:10.5811/westjem.2019.10.43497.
420	3. Stein JC, Navab B, Frazee B, Tebb K, Hendey G, Maselli J, et al. A randomized trial of
421	computer kiosk-expedited management of cystitis in the emergency department. Acad Emerg
422	Med. 2011;18(10):1053-1059. doi:10.1111/j.1553-2712.2011.01167.x.
423	4. Bashshur RL, Reardon TG, Shannon GW. Telemedicine: a new health care delivery
424	system. Annu Rev Public Health. 2000;21:613-637. doi:10.1146/annurev.publhealth.21.1.613.
425	5. Bono MJ, Leslie SW, Reygaert WC. Urinary tract infection. In: StatPearls [Internet].
426	Treasure Island (FL): StatPearls Publishing; 2022.
427	6. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines
428	in the treatment of uncomplicated urinary tract infection. Clin Infect Dis. 2007;44(6):769-774.
429	doi:10.1086/511866.
430	7. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk
431	factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13.
432	doi:10.1016/j.idc.2013.09.003.
433	8. Ozturk T, Talo M, Yildirim EA, Baloglu UB, Yildirim O, Acharya UR. Automated
434	detection of COVID-19 cases using deep neural networks with X-ray images. Comput Biol Med.
435	2020;121:103792. doi:10.1016/j.compbiomed.2020.103792.

436	9.	Campbell J, Felver M, Kamarei S. 'Telephone treatment' of uncomplicated acute cystitis.
437	Cleve	Clin J Med. 1999;66(8):495-501. doi:10.3949/ccjm.66.8.495.
438	10.	Saint S, Scholes D, Fihn SD, Farrell RG, Stamm WE. The effectiveness of a clinical
439	practi	ce guideline for the management of presumed uncomplicated urinary tract infection in
440	wome	en. Am J Med. 1999;106(6):636-641. doi:10.1016/s0002-9343(99)00122-9.
441	11.	Barry HC, Hickner J, Ebell MH, Ettenhofer T. A randomized controlled trial of telephone
442	manag	gement of suspected urinary tract infections in women. J Fam Pract. 2001;50(7):589-594.
443	12.	Vinson DR, Quesenberry CP, Jr. The safety of telephone management of presumed
444	cystiti	is in women. Arch Intern Med. 2004;164(9):1026-1029. doi:10.1001/archinte.164.9.1026.
445	13.	Schauberger CW, Merkitch KW, Prell AM. Acute cystitis in women: experience with a
446	teleph	none-based algorithm. WMJ. 2007;106(6):326-329.
447	14.	Bollestad M, Grude N, Lindbaek M. A randomized controlled trial of a diagnostic
448	algori	thm for symptoms of uncomplicated cystitis at an out-of-hours service. Scand J Prim
449	Healtl	h Care. 2015;33(2):57-64. doi:10.3109/02813432.2015.1041827.
450	15.	Rastogi R, Martinez KA, Gupta N, Rood M, Rothberg MB. Management of urinary tract
451	infect	ions in direct to consumer telemedicine. J Gen Intern Med. 2020;35(3):643-648.
452	doi:10	0.1007/s11606-019-05415-7.
453	16.	Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute
454	uncon	nplicated urinary tract infection? JAMA. 2002;287(20):2701-2710.
455	doi:1(0.1001/jama.287.20.2701.
456	17.	Little P, Moore MV, Turner S, Rumsby K, Warner G, Lowes JA, et al. Effectiveness of
457	five d	ifferent approaches in management of urinary tract infection: randomised controlled trial.
458	BMJ.	2010;340:c199. doi:10.1136/bmj.c199.

- 459 18. Gupta K, Grigoryan L, Trautner B. Urinary tract infection. Ann Intern Med.
- 460 2017;167(7):ITC49-ITC64. doi:10.7326/aitc201710030.
- 461 19. Sabih A, Leslie SW. Complicated urinary tract infections. 2022 May 27. In: StatPearls
- 462 [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
- 463 20. Smith WB, II, Kohlwes RJ. From leather bags to webcams, the emerging tools of tele-
- 464 primary care. J Gen Intern Med. 2020;35(3):628-629. doi:10.1007/s11606-019-05603-5.
- 465 21. Giesen LGM, Cousins G, Dimitrov BD, van de Laar FA, Fahey T. Predicting acute
- 466 uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy
- 467 of symptoms and signs. BMC Fam Pract. 2010;11:78. doi:10.1186/1471-2296-11-78.
- 468 22. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am
- 469 Fam Physician. 2011;84(7):771-776.
- 470 23. Garland SM, Tabrizi SN. Diagnosis of sexually transmitted infections (STI) using self-
- 471 collected non-invasive specimens. Sex Health. 2004;1(2):121-126. doi:10.1071/sh03014.
- 472 24. Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FM. Reliability of
- 473 symptom-based diagnosis of uncomplicated cystitis. Urol Int. 2019;102(1):83-95.
- 474 doi:10.1159/000493509.
- 475 25. Goebel MC, Trautner BW, Grigoryan L. The five Ds of outpatient antibiotic stewardship
 476 for urinary tract infections. Clin Microbiol Rev. 2021;34(4):e0000320. doi:10.1128/cmr.00003-
- **477** 20.
- 478 26. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract
- 479 infections in the outpatient setting: a review. JAMA. 2014;312(16):1677-1684.
- 480 doi:10.1001/jama.2014.12842.

- 481 27. U.S. Department of Health and Human Services. Complicated urinary tract infections:
- 482 developing drugs for treatment. Guidance for industry. 2018. Available at
- 483 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-
- 484 urinary-tract-infections-developing-drugs-treatment. Accessed on April 20, 2022.
- 485 28. Belyayeva M, Jeong JM. Acute pyelonephritis. 2022 Jul 5. In: StatPearls [Internet].
- 486 Treasure Island (FL): StatPearls Publishing; 2022.
- 487 29. Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus
- trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in
- 489 general practice. J Antimicrob Chemother. 1994;33 Suppl A:121-129.
- 490 doi:10.1093/jac/33.suppl_a.121.
- 491 30. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in
- 492 female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21(11):1864-1872.
- 493 doi:10.1016/s0149-2918(00)86734-x.
- 494 31. Kavatha D, Giamarellou H, Alexiou Z, Vlachogiannis N, Pentea S, Gozadinos T, et al.
- 495 Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of
- 496 uncomplicated acute cystitis in women. Antimicrob Agents Chemother. 2003;47(3):897-900.
- doi:10.1128/aac.47.3.897-900.2003.
- 498 32. Arredondo-García JL, Figueroa-Damián R, Rosas A, Jáuregui A, Corral M, Costa A, et
- al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment
- 500 regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract
- 501 infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother.
- 502 2004;54(4):840-843. doi:10.1093/jac/dkh414.

- 503 33. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. Clinical and bacteriological
- 504 outcome of different doses and duration of pivmecillinam compared with placebo therapy of
- 505 uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health
- 506 Care. 2007;25(1):49-57. doi:10.1080/02813430601183074.
- 507 34. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the
- treatment of acute uncomplicated cystitis in women. Arch Intern Med. 2007;167(20):2207-2212.
- 509 doi:10.1001/archinte.167.20.2207.
- 510 35. Blozik E, Sommer-Meyer C, Cerezo M, von Overbeck J. Effectiveness and safety of
- telemedical management in uncomplicated urinary tract infections. 2011;17(2):78-82.
- 512 doi:10.1258/jtt.2010.100406.
- 513 36. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of
- 514 uncomplicated recurrent urinary tract infections in young women. Ann Intern Med.
- 515 2001;135(1):9-16. doi:10.7326/0003-4819-135-1-200107030-00004.
- 516 37. Zatorski C, Zocchi M, Cosgrove SE, Rand C, Brooks G, May L. A single center
- 517 observational study on emergency department clinician non-adherence to clinical practice
- 518 guidelines for treatment of uncomplicated urinary tract infections. BMC Infect Dis.
- 519 2016;16(1):638. doi:10.1186/s12879-016-1972-6.
- 520 38. Grigoryan L, Zoorob R, Wang H, Trautner BW. Low concordance with guidelines for
- treatment of acute cystitis in primary care. Open Forum Infect Dis. 2015;2(4):ofv159.
- 522 doi:10.1093/ofid/ofv159.
- 523 39. Grigoryan L, Nash S, Zoorob R, Germanos GJ, Horsfield MS, Khan FM, et al.
- 524 Qualitative analysis of primary care provider prescribing decisions for urinary tract infections.
- 525 Antibiotics (Basel). 2019;8(2). doi:10.3390/antibiotics8020084.

- 526 40. Gupta K, Hooton TM, Naber KG, Wult B, Colgan R, Miller LG, et al. International
- 527 clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in
- 528 women: a 2010 update by the Infectious Diseases Society of America and the European Society
- for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120.
- 530 doi:10.1093/cid/ciq257.

531 S1 Appendix: Prescription Information

Recommended Regimens						
Nitrofurantoin 100 mg, twice per day for 5 days	Trimethoprim-sulfamethoxazole 160–800 mg twice per day for 3 days	Fosfomycin 3 g single dose				
Alternative Regimens						
Ciprofloxacin [*] 250 mg twice per day for 3 days	Ciprofloxacin extended release [*] 500 mg once per day for 3 days	Levofloxacin [*] 250 mg once per day for 3 days				
Ofloxacin [*] 400 mg single dose	Amoxicillin-clavulanate [†] 500–125 mg twice per day for 3–7 days	Cefpodoxime [†] 100 mg twice per day for 3–7 days				
Cefdinir [†] 300 mg twice per day for 3–7 days	Cefaclor [†] 250 mg or 500 mg 3 times per day for 3–7 days	Cefadroxil [†] 500 mg twice per day for 3–7 days				

532 ^{*}Fluoroquinolones

533 [†]Beta lactams